<DOC>
<DOCNO>
EP-0011606
</DOCNO>
<TEXT>
<DATE>
19800528
</DATE>
<IPC-CLASSIFICATIONS>
C07D-405/04 A61K-31/44 A61P-25/00 C07D-405/00 A61K-31/443 A61P-25/18 A61K-31/4427 A61K-31/445 
</IPC-CLASSIFICATIONS>
<TITLE>
pharmaceutical compositions with central depressing and antipsychotic activity
</TITLE>
<APPLICANT>
ciba geigy agch <sep>ciba-geigy ag<sep>ciba-geigy ag klybeckstrasse 141 4002 baselch<sep>
</APPLICANT>
<INVENTOR>
delini-stula aleksandra drch<sep>waldmeier peter drch<sep>delini-stula, aleksandra, dr.<sep>waldmeier, peter, dr.<sep>delini-stula, aleksandra, dr.neubadstrasse 72ch-4054 baselch<sep>waldmeier, peter, dr.passwangstrasse 17ch-4153 reinachch<sep>
</INVENTOR>
<ABSTRACT>
The invention relates to pharmaceutical preparations with centrimental and antipsychotic effectiveness, which as active substances a centrative and antipsychotic effective, in 4-position basic butyrophen derivative, in particular one of the alcohal formula I <Image> in which PIP is a 4,4-disubstituted or 4- Substituted piperidinorest, or a pharmaceutically acceptable acid addition salt of such and optionally substituted C- (2-benzofuranyl) piperidine or C- (2-benzofuranyl) tetrahydropyridine of the general formula II <Image> in which R1 is hydrogen, an alkyl group with at most 4 carbon atoms, the allyl, 3-oxobutyl, 3-hydroxybutyl, 2-propinyl or cyclopropylmethyl group, R2 hydrogen or a methyl group, R3 hydrogen, halogen to atomic number 35, a lower alkyl or alkoxy group, the trifluoromethyl group or a cycloalkyl group with 5-8 carbon atoms, R4 hydrogen a lower alkyl group or halogen to atomic number 35, or as R1 and R4 together a 1,3-butadiene residue in 4,5-position, corresponding to a cultured benzene ring, or a trimethylene residue in 5,6-position, a the aethylene group and b the methylene group or A the methylene group and B are the aethylene group, and X and Y per hydrogen or together an additional bond, or a pharmaceutically acceptable acid addition salt of such a contain.
</ABSTRACT>
</TEXT>
</DOC>
